-
the development of new cancer therapies. Few UBE2N inhibitors have been described in the literature, and these are mainly covalent inhibitors, which, due to a lack of selectivity, expose patients
-
dependent not only on its current state but also on its past evolution. These effects emerge because the discarded degrees of freedom—considered as part of the environment—continue to influence the system
Enter an email to receive alerts for evolution "https:" "https:" "https:" positions